×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: Mitochondrial Dysfunction in Progressive Supranuclear Palsy
mechanism
3,494 words
KG: ent-dise-bfd8f32d
2026-03-24
kind:mechanism
section:mechanisms
state:published
Contents
Mitochondrial Dysfunction in Progressive Supranuclear Palsy
⚙
Mechanism Info
Name
Mitochondrial Dysfunction in Progressive Supranuclear Palsy
Summary
Page for Mitochondrial Dysfunction in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (30)
Microbial Inflammasome Priming Prevention
Score: 0.58
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.45
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.45
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.47
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Mitochondrial Transfer Pathway Enhancement
Score: 0.44
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.42
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.41
Mitochondrial RNA Granule Rescue Pathway
Score: 0.40
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.38
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.38
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
Astrocytic Connexin-43 Upregulation Enhances Neuroprotective
Score: 0.45
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.43
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
Brain Insulin Resistance with Glucose Transporter Dysfunctio
Score: 0.40
Show 25 more
Related Analyses (30)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Show 25 more
Related Experiments (28)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Show 23 more